<!DOCTYPE html>
<html lang="en" xml:lang="en">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 6 Kidney allocation in Eurotransplant | Organ allocation models in Eurotransplant</title>
  <meta name="description" content="This is the PhD thesis of H.C. de Ferrante" />
  <meta name="generator" content="bookdown 0.42 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 6 Kidney allocation in Eurotransplant | Organ allocation models in Eurotransplant" />
  <meta property="og:type" content="book" />
  <meta property="og:image" content="/cover/thesis_cover.png" />
  <meta property="og:description" content="This is the PhD thesis of H.C. de Ferrante" />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 6 Kidney allocation in Eurotransplant | Organ allocation models in Eurotransplant" />
  
  <meta name="twitter:description" content="This is the PhD thesis of H.C. de Ferrante" />
  <meta name="twitter:image" content="/cover/thesis_cover.png" />

<meta name="author" content="Hans Christiaan de Ferrante" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="CHelassimulator.html"/>
<link rel="next" href="CHvpra.html"/>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>
<script src="libs/kePrint-0.0.1/kePrint.js"></script>
<link href="libs/lightable-0.0.1/lightable.css" rel="stylesheet" />
<link href="libs/bsTable-3.3.7/bootstrapTable.min.css" rel="stylesheet" />
<script src="libs/bsTable-3.3.7/bootstrapTable.js"></script>



<style type="text/css">
  
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
</style>
<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
  margin-bottom: 0em;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="" data-path="dankwoord.html"><a href="dankwoord.html"><i class="fa fa-check"></i>Dankwoord</a></li>
<li class="chapter" data-level="1" data-path="CHintroduction.html"><a href="CHintroduction.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li class="chapter" data-level="1.1" data-path="CHintroduction.html"><a href="CHintroduction.html#eurotransplant"><i class="fa fa-check"></i><b>1.1</b> Eurotransplant</a></li>
<li class="chapter" data-level="1.2" data-path="CHintroduction.html"><a href="CHintroduction.html#objective-medical-criteria-for-organ-allocation"><i class="fa fa-check"></i><b>1.2</b> Objective medical criteria for organ allocation</a></li>
<li class="chapter" data-level="1.3" data-path="CHintroduction.html"><a href="CHintroduction.html#fairness-in-organ-allocation"><i class="fa fa-check"></i><b>1.3</b> Fairness in organ allocation</a></li>
<li class="chapter" data-level="1.4" data-path="CHintroduction.html"><a href="CHintroduction.html#challenges-in-improving-organ-allocation-systems"><i class="fa fa-check"></i><b>1.4</b> Challenges in improving organ allocation systems</a></li>
<li class="chapter" data-level="1.5" data-path="CHintroduction.html"><a href="CHintroduction.html#outline-of-this-thesis"><i class="fa fa-check"></i><b>1.5</b> Outline of this thesis</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html"><i class="fa fa-check"></i><b>2</b> Liver allocation in Eurotransplant</a>
<ul>
<li class="chapter" data-level="2.1" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#liver-allocation-prior-to-meld"><i class="fa fa-check"></i><b>2.1</b> Liver allocation prior to MELD</a></li>
<li class="chapter" data-level="2.2" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#meld-based-liver-allocation-in-the-united-states"><i class="fa fa-check"></i><b>2.2</b> MELD-based liver allocation in the United States</a></li>
<li class="chapter" data-level="2.3" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#meld-based-liver-allocation-in-eurotransplant"><i class="fa fa-check"></i><b>2.3</b> MELD-based liver allocation in Eurotransplant</a></li>
<li class="chapter" data-level="2.4" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#areas-for-improvement-in-meld-based-allocation-systems"><i class="fa fa-check"></i><b>2.4</b> Areas for improvement in MELD-based allocation systems</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="CHdynremeld.html"><a href="CHdynremeld.html"><i class="fa fa-check"></i><b>3</b> Revising MELD from calendar-time cross-sections with correction for selection bias</a>
<ul>
<li class="chapter" data-level="3.1" data-path="CHdynremeld.html"><a href="CHdynremeld.html#introduction"><i class="fa fa-check"></i><b>3.1</b> Introduction</a></li>
<li class="chapter" data-level="3.2" data-path="CHdynremeld.html"><a href="CHdynremeld.html#materials-and-methods"><i class="fa fa-check"></i><b>3.2</b> Materials and methods</a></li>
<li class="chapter" data-level="3.3" data-path="CHdynremeld.html"><a href="CHdynremeld.html#results"><i class="fa fa-check"></i><b>3.3</b> Results</a></li>
<li class="chapter" data-level="3.4" data-path="CHdynremeld.html"><a href="CHdynremeld.html#discussion"><i class="fa fa-check"></i><b>3.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html"><i class="fa fa-check"></i><b>4</b> Sex disparity in liver allocation within Eurotransplant</a>
<ul>
<li class="chapter" data-level="4.1" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#introduction-1"><i class="fa fa-check"></i><b>4.1</b> Introduction</a></li>
<li class="chapter" data-level="4.2" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#materials-and-methods-1"><i class="fa fa-check"></i><b>4.2</b> Materials and methods</a></li>
<li class="chapter" data-level="4.3" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#results-1"><i class="fa fa-check"></i><b>4.3</b> Results</a></li>
<li class="chapter" data-level="4.4" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#discussion-1"><i class="fa fa-check"></i><b>4.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="CHelassimulator.html"><a href="CHelassimulator.html"><i class="fa fa-check"></i><b>5</b> The ELAS simulator</a>
<ul>
<li class="chapter" data-level="5.1" data-path="CHelassimulator.html"><a href="CHelassimulator.html#introduction-2"><i class="fa fa-check"></i><b>5.1</b> Introduction</a></li>
<li class="chapter" data-level="5.2" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elassystem"><i class="fa fa-check"></i><b>5.2</b> The Eurotransplant Liver Allocation System (ELAS)</a></li>
<li class="chapter" data-level="5.3" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasdesign"><i class="fa fa-check"></i><b>5.3</b> The design of the ELAS simulator</a></li>
<li class="chapter" data-level="5.4" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasmodules"><i class="fa fa-check"></i><b>5.4</b> Modules of the ELAS simulator</a></li>
<li class="chapter" data-level="5.5" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasvv"><i class="fa fa-check"></i><b>5.5</b> Verification and validation</a></li>
<li class="chapter" data-level="5.6" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elascasestudies"><i class="fa fa-check"></i><b>5.6</b> Case studies: the impact of modifying ELAS rules</a></li>
<li class="chapter" data-level="5.7" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasconclusion"><i class="fa fa-check"></i><b>5.7</b> Conclusions and discussion</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html"><i class="fa fa-check"></i><b>6</b> Kidney allocation in Eurotransplant</a>
<ul>
<li class="chapter" data-level="6.1" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#hla-matching-versus-fairness"><i class="fa fa-check"></i><b>6.1</b> HLA matching versus fairness</a></li>
<li class="chapter" data-level="6.2" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#kidney-allocation-programs-in-eurotransplant"><i class="fa fa-check"></i><b>6.2</b> Kidney allocation programs in Eurotransplant</a></li>
<li class="chapter" data-level="6.3" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#contemporary-challenges-in-kidney-allocation"><i class="fa fa-check"></i><b>6.3</b> Contemporary challenges in kidney allocation</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="CHvpra.html"><a href="CHvpra.html"><i class="fa fa-check"></i><b>7</b> Access to transplantation for immunized candidates</a>
<ul>
<li class="chapter" data-level="7.1" data-path="CHvpra.html"><a href="CHvpra.html#introduction-3"><i class="fa fa-check"></i><b>7.1</b> Introduction</a></li>
<li class="chapter" data-level="7.2" data-path="CHvpra.html"><a href="CHvpra.html#materials-and-methods-2"><i class="fa fa-check"></i><b>7.2</b> Materials and methods</a></li>
<li class="chapter" data-level="7.3" data-path="CHvpra.html"><a href="CHvpra.html#results-2"><i class="fa fa-check"></i><b>7.3</b> Results</a></li>
<li class="chapter" data-level="7.4" data-path="CHvpra.html"><a href="CHvpra.html#discussion-2"><i class="fa fa-check"></i><b>7.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="8" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html"><i class="fa fa-check"></i><b>8</b> The ETKidney simulator</a>
<ul>
<li class="chapter" data-level="8.1" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#introduction-4"><i class="fa fa-check"></i><b>8.1</b> Introduction</a></li>
<li class="chapter" data-level="8.2" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneyalloc"><i class="fa fa-check"></i><b>8.2</b> The kidney allocation programs of Eurotransplant</a></li>
<li class="chapter" data-level="8.3" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneydesign"><i class="fa fa-check"></i><b>8.3</b> Purpose and design of the ETKidney Simulator</a></li>
<li class="chapter" data-level="8.4" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneymodules"><i class="fa fa-check"></i><b>8.4</b> Modules of the ETKidney simulator</a></li>
<li class="chapter" data-level="8.5" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneyvv"><i class="fa fa-check"></i><b>8.5</b> Verification and validation</a></li>
<li class="chapter" data-level="8.6" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneycasestudies"><i class="fa fa-check"></i><b>8.6</b> Case studies</a></li>
<li class="chapter" data-level="8.7" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneydiscussion"><i class="fa fa-check"></i><b>8.7</b> Discussion and conclusion</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="CHdiscussion.html"><a href="CHdiscussion.html"><i class="fa fa-check"></i><b>9</b> The way forward</a>
<ul>
<li class="chapter" data-level="9.1" data-path="CHdiscussion.html"><a href="CHdiscussion.html#this-thesis-is-a-sharp-look-at-familiar-problems"><i class="fa fa-check"></i><b>9.1</b> This thesis is a sharp look at familiar problems</a></li>
<li class="chapter" data-level="9.2" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-need-to-look-beyond-survival-models-for-allocation"><i class="fa fa-check"></i><b>9.2</b> We need to look beyond survival models for allocation</a></li>
<li class="chapter" data-level="9.3" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-should-look-beyond-aggregate-outcomes"><i class="fa fa-check"></i><b>9.3</b> We should look beyond aggregate outcomes</a></li>
<li class="chapter" data-level="9.4" data-path="CHdiscussion.html"><a href="CHdiscussion.html#scientific-evidence-is-rarely-the-bottleneck"><i class="fa fa-check"></i><b>9.4</b> Scientific evidence is rarely the bottleneck</a></li>
<li class="chapter" data-level="9.5" data-path="CHdiscussion.html"><a href="CHdiscussion.html#the-chicken-and-egg-problem-in-allocation-development"><i class="fa fa-check"></i><b>9.5</b> The “chicken-and-egg” problem in allocation development</a></li>
<li class="chapter" data-level="9.6" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-need-more-constructive-dialogue"><i class="fa fa-check"></i><b>9.6</b> We need more constructive dialogue</a></li>
</ul></li>
<li class="appendix"><span><b>Appendix</b></span></li>
<li class="chapter" data-level="A" data-path="APPipcw.html"><a href="APPipcw.html"><i class="fa fa-check"></i><b>A</b> Inverse Probability Censoring Weights</a>
<ul>
<li class="chapter" data-level="" data-path="APPipcw.html"><a href="APPipcw.html#definition-of-ipcw-weights"><i class="fa fa-check"></i>Definition of IPCW weights</a></li>
</ul></li>
<li class="chapter" data-level="B" data-path="APPimputation.html"><a href="APPimputation.html"><i class="fa fa-check"></i><b>B</b> Completing the status updates streams for transplant recipients</a>
<ul>
<li class="chapter" data-level="B.1" data-path="APPimputation.html"><a href="APPimputation.html#step-1-and-2-construction-of-the-pseudo-observations"><i class="fa fa-check"></i><b>B.1</b> Step 1 and 2: Construction of the pseudo-observations</a></li>
<li class="chapter" data-level="B.2" data-path="APPimputation.html"><a href="APPimputation.html#step-3-fitting-a-model-for-the-mean-restricted-survival-time"><i class="fa fa-check"></i><b>B.2</b> Step 3: Fitting a model for the mean restricted survival time</a></li>
<li class="chapter" data-level="B.3" data-path="APPimputation.html"><a href="APPimputation.html#step-4-constructing-future-statuses"><i class="fa fa-check"></i><b>B.3</b> Step 4: Constructing future statuses</a></li>
<li class="chapter" data-level="B.4" data-path="APPimputation.html"><a href="APPimputation.html#step-4.2-matching-the-patient-to-a-particular-patient-in-the-risk-set"><i class="fa fa-check"></i><b>B.4</b> Step 4.2: Matching the patient to a particular patient in the risk set</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="summary.html"><a href="summary.html"><i class="fa fa-check"></i>Summary</a></li>
<li class="chapter" data-level="" data-path="course-of-life.html"><a href="course-of-life.html"><i class="fa fa-check"></i>Course of Life</a></li>
<li class="chapter" data-level="" data-path="list-of-publications.html"><a href="list-of-publications.html"><i class="fa fa-check"></i>List of publications</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Organ allocation models in Eurotransplant</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="CHprefacekidney" class="section level1 hasAnchor" number="6">
<h1><span class="header-section-number">Chapter 6</span> Kidney allocation in Eurotransplant<a href="CHprefacekidney.html#CHprefacekidney" class="anchor-section" aria-label="Anchor link to header"></a></h1>
<p>Up to 100 million Europeans have Chronic Kidney Disease (CKD) <span class="citation"><a href="#ref-Vanholder2021">[104]</a></span>.
CKD is characterized by the progressive loss of kidney function, and its causes
include diabetes, hypertension, and glomerulonephritis. Patients with CKD
can eventually progress to End-Stage Renal Disease (ESRD), which means that they
become dependent on renal replacement therapies (RRTs) such as dialysis or
kidney transplantation. Whereas other forms of end-stage organ failure cannot
be managed with therapy, end-stage kidney failure can be managed for extended
periods with dialysis <span class="citation"><a href="#ref-HaaseKromwijk1999">[7]</a></span>.
However, kidney transplantation is the preferred treatment option for most
patients with ESRD because it is associated with a reduction in patient mortality
and improves the patient’s quality of life <span class="citation"><a href="#ref-Tonelli2011">[105]</a></span>.</p>
<p>Kidney transplantation became the preferred treatment option for patients with
ESRD in the 1980s, when substantial improvements were observed in post-transplant
outcomes <span class="citation"><a href="#ref-HaaseKromwijk1999">[7]</a></span>. As a result, the kidney waiting list in Eurotransplant
expanded from less than 2,000 patients in 1980
to approximately 10,500 patients in 1994 <span class="citation"><a href="#ref-eurotransplantAR2005">[106]</a></span>. Since then, the number of patients awaiting kidney transplantation has remained stable in
Eurotransplant with approximately 10,000 patients currently waiting for a kidney transplant.</p>
<p>Eurotransplant allocates kidneys from deceased-organ donors to these waiting patients.
When Eurotransplant was initiated, candidates were prioritized solely based
on Human Leucocyte Antigen (HLA) matching. Currently,
Eurotransplant uses an allocation system which tries to balance HLA matching
with fairness considerations. In this chapter, we describe the history of this
system and some contemporary challenges in the allocation of deceased-donor kidneys.
We also briefly describe the work included in this thesis that can inform
discussions on addressing these challenges.</p>
<div id="hla-matching-versus-fairness" class="section level2 hasAnchor" number="6.1">
<h2><span class="header-section-number">6.1</span> HLA matching versus fairness<a href="CHprefacekidney.html#hla-matching-versus-fairness" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>In the late 1960s, immunologists observed that the best outcomes after kidney
transplantation were observed in pairs of siblings who had compatible ABO blood groups
and matching leukocyte antigen groups <span class="citation"><a href="#ref-vanDorp2001">[107]</a></span>. Anticipating that
such a matching effect also existed when transplanting kidneys from deceased donors,
Jon van Rood proposed Eurotransplant, a program in which a central office
would use a computer to locate the best-matching candidate for the kidneys that
became available from deceased donors <span class="citation"><a href="#ref-vanRoodET1967">[1]</a></span>.
Shortly after Eurotransplant was initiated in 1967, similar organizations were
established in other geographic regions, motivated by the idea that outcomes after
deceased-donor transplantation could only be improved through collaboration <span class="citation"><a href="#ref-bakJensenShareNotShare2008">[108]</a></span>.</p>
<p>Already in 1970, this idea became controversial with a strong debate emerging between
immunologists and clinicians on the actual importance of leukocyte-antigen
matching in deceased-donor kidney transplantation <span class="citation"><a href="#ref-daussetHLAStory1995">[109]</a>, <a href="#ref-vanRood2004">[110]</a></span>.
The commitment of immunologists to HLA matching was strengthened in the 1970s
and 1980s, as they unraveled many complexities of what became known
as the Human Leucocyte Antigen (HLA) system. The discovery of HLA-DR antigens in 1977
was particularly important, as these antigens were shown to have a stronger effect
on prognosis after kidney transplantation than the earlier discovered HLA-A
and HLA-B antigens <span class="citation"><a href="#ref-bakJensenShareNotShare2008">[108]</a>, <a href="#ref-Persijn1978">[111]</a>, <a href="#ref-Persijn1981">[112]</a></span>.</p>
<p>At the same time, it was recognized that HLA matching was far from a magic bullet;
many patients with poorly matched kidneys had good outcomes after
transplantation <span class="citation"><a href="#ref-vanRood2004">[110]</a>, <a href="#ref-terasaki1990history">[113]</a></span>. Based on such observations,
clinicians questioned whether HLA matching was worth the effort, especially because
the practice resulted in disparities in access to transplantation <span class="citation"><a href="#ref-Kjellstrand1988">[114]</a></span>.
For example, in the United States, it was observed that black patients were waiting
three times longer than white patients for a kidney transplant.
Thomas Starzl, who is known as “the father of modern transplantation”, criticized the blind focus
on HLA matching in kidney allocation, referring to it as <em>“the institutional
organization of racial bias”</em> <span class="citation"><a href="#ref-vanDorp2001">[107, p. 159]</a></span>. To reduce such disparities,
Starzl’s transplant center instead used a point system to prioritize candidates
for transplantation, in which tissue matching played a role that was
<em>“significant but far from overriding”</em> <span class="citation"><a href="#ref-starzlMultifactorialSystemEquitable1987">[115]</a></span>.</p>
<p>This criticism of HLA matching intensified in the 1980s with the advent of cyclosporine
A. This immunosuppressant strongly reduced the incidence of acute rejection of kidney
transplants, and was responsible for the major improvements in kidney transplant
outcomes that were observed in the 1980s. Shortly after the introduction of
cyclosporine A, several single-center studies
suggested that this immunosuppressant had made HLA matching in kidney transplantation
redundant <span class="citation"><a href="#ref-greensteinEvidenceThatZero1990">[116]</a>, <a href="#ref-harfmannRenalTransplantationUsing1989">[117]</a></span>.
These early findings have since been contradicted by multi-center and
registry-based studies, which showed that HLA matching continues to be strongly
associated with graft and patient survival <span class="citation"><a href="#ref-opelzCORRELATIONHLAMATCHING1985">[118]</a>, <a href="#ref-Opelz2007">[119]</a></span>.
Based on these later studies, consensus has arisen that the best outcomes are observed
in patients who receive transplants with zero mismatches on the HLA-A, HLA-B,
and HLA-DR loci <span class="citation"><a href="#ref-opelzCORRELATIONHLAMATCHING1985">[118]</a>, <a href="#ref-morrisAnalysisFactorsThat1999">[120]</a></span>. However,
the extensive polymorphism of the HLA system means that perfectly matched kidneys
are not available for most candidates. In fact, it was already known in the 1980s
that only about one in five patients can receive a perfectly matched kidney
with a waiting list of 10,000 patients <span class="citation"><a href="#ref-CICCIARELLI1987">[121]</a></span>. Most patients
thus have to settle for a kidney with HLA mismatches. In that case, consensus is
that HLA-DR matching is more important than HLA-B matching, which in turn is more
important than HLA-A matching <span class="citation"><a href="#ref-Ting1985">[122]</a>, <a href="#ref-joyseyTissueTypingPolicy1989">[123]</a>, <a href="#ref-thorogood1990">[124]</a></span>.</p>
<p>Because of the role of HLA matching was contended, kidney allocation first
became more decentralized in the 1980s <span class="citation"><a href="#ref-bakJensenShareNotShare2008">[108]</a></span>. For example,
in 1988 Eurotransplant introduced a kidney allocation system that mandated
exchange of kidneys between centers only for (a) patients who had zero HLA mismatches
with the kidney and (b) the so-called “<em>hyper-immunized patients</em>” (see Section <a href="CHprefacekidney.html#sec:introam">6.2.2</a>)
<span class="citation"><a href="#ref-HaaseKromwijk1999">[7]</a></span>. Otherwise, the center responsible for procurement of the kidneys
could choose patients from their own waiting list for transplantation, subject to blood group
compatibility rules and minimum HLA match criteria (defined as 2 DR matches, or
1 B + 1 DR match) <span class="citation"><a href="#ref-HaaseKromwijk1999">[7]</a></span>. Procurement centers also had the option to
voluntarily offer the kidneys to the Eurotransplant pool. Candidates would then be prioritized by
compatibility at the HLA-DR locus, followed by compatibility at the HLA-B locus,
and finally compatibility at the HLA-A locus <span class="citation"><a href="#ref-HaaseKromwijk1999">[7]</a></span>.</p>
<p>When Eurotransplant evaluated this system in the 1990s, concerns were raised
over the fact that (i) 10 percent of patients consistently waited more than five years
for kidney transplantation, (ii) transplant rates were low for candidates with
rare HLA types or homozygosity at any of the HLA loci, and (iii) procurement
and transplant rates were imbalanced between the centers and countries
<span class="citation"><a href="#ref-DeMeester1998_booksection">[125]</a></span>. These fairness concerns
eventually led to the adoption of the Eurotransplant Kidney Allocation System
(ETKAS) in 1996, which was based on a point system that had been proposed by
Wujciak and Opelz in the years before. Besides this program, Eurotransplant
has used two other programs to allocate deceased-donor kidneys since the 1990s:
the Acceptable Mismatch (AM) program for the allocation of kidneys to hyper-immunized candidates (Section
<a href="CHprefacekidney.html#sec:introam">6.2.2</a>), and the Eurotransplant Senior Program (ESP) for the allocation
of kidneys from donors aged 65 years or older (Section <a href="CHprefacekidney.html#sec:introesp">6.2.3</a>).</p>
<p></p>
</div>
<div id="kidney-allocation-programs-in-eurotransplant" class="section level2 hasAnchor" number="6.2">
<h2><span class="header-section-number">6.2</span> Kidney allocation programs in Eurotransplant<a href="CHprefacekidney.html#kidney-allocation-programs-in-eurotransplant" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<div id="the-eurotransplant-kidney-allocation-system-etkas" class="section level3 hasAnchor" number="6.2.1">
<h3><span class="header-section-number">6.2.1</span> The Eurotransplant Kidney Allocation System (ETKAS)<a href="CHprefacekidney.html#the-eurotransplant-kidney-allocation-system-etkas" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Wujciak and Opelz tried to address the dilemma between HLA
matching and fairness by using computer simulations to develop a point system
for kidney allocation <span class="citation"><a href="#ref-wujciakProposalImprovedCadaver1993a">[126]</a>, <a href="#ref-Opelz1998">[127]</a></span>. This
system awarded points for the absence of HLA mismatches, but also points for
a candidate’s waiting time to ensure that no candidate would be left behind.
Additionally, to avoid extreme waiting times for difficult-to-match patients,
the system awarded points for the <em>“mismatch probability”</em>, a quantification of
how common favorably matched kidneys are for the patient.</p>
<p>Eurotransplant implemented a modified version of this point system for kidney
allocation in 1996, and the resulting program has become known as the
Eurotransplant Kidney Allocation System (ETKAS) program. The modifications made
included that ETKAS awards extra priority to pediatric candidates, and implements
a mechanism to balance the international transfer of kidneys <span class="citation"><a href="#ref-Opelz1998">[127]</a></span>.</p>
<p>One year after the introduction of ETKAS, in 1997, it was concluded that ETKAS
successfully achieved its primary goals; the system had increased the number of transplantations
among pediatric and long-waiting candidates and it had corrected imbalances in
the international exchange of kidneys <span class="citation"><a href="#ref-Persijn2006">[8]</a>, <a href="#ref-demeesterNewEurotransplantKidney1998">[15]</a></span>.
Despite this apparent success, it was also pointed out by Wujciak and Opelz that
ETKAS <em>“could not be considered a final and unalterable product”</em>, which instead
would require <em>“continued fine-tuning depending on new developments”</em> <span class="citation"><a href="#ref-Opelz1998">[127]</a></span>.</p>
<p>In light of these comments, it is not surprising that several refinements have
been made to ETKAS since 1996. One refinement concerns the definition of
waiting time. When ETKAS was initiated, waiting time was defined as the number of days
a candidate had spent on the waiting list, which conferred an advantage to patients
who were referred early to the kidney waiting list. To address this, Eurotransplant
redefined waiting time to the number of days a candidate had received dialysis
in January 2000 <span class="citation"><a href="#ref-DeMeester2000">[128]</a></span>. A second issue was that ABO
blood group O kidneys could be transplanted in non-O candidates in case of
a zero mismatch, which led to an increased waiting list mortality and longer
waiting times for blood group O patients <span class="citation"><a href="#ref-glander2010">[17]</a></span>. In June 2010, this
issue was addressed by always requiring candidates and donors to have identical
ABO blood groups in ETKAS.</p>
<p>Shortcomings of ETKAS have also been identified for which an adequate solution
has remained elusive. A notable example is that the ETKAS point system places
equal emphasis on the HLA-A, HLA-B and HLA-DR loci, which has been described to lead to
additional mismatches on the HLA-DR locus
<span class="citation"><a href="#ref-demeesterNewEurotransplantKidney1998">[15]</a>, <a href="#ref-vereerstraetenExperienceWujciakOpelzAllocation1998">[129]</a></span>.
Several proposals have
been made to instead emphasize HLA-DR matching in ETKAS (e.g., Doxiadis et al. <span class="citation"><a href="#ref-doxiadisSimplerEquitableAllocation2007">[130]</a></span>)
which have been rejected by national competent authorities (e.g., Heemskerk et al. <span class="citation"><a href="#ref-heemskerkRegionalKidneyAllocation2009">[131]</a></span>).
As a result, ETKAS still places equal emphasis on HLA matching at the A locus
as on matching at the DR locus.</p>
<p>Another example of such a shortcoming are the mismatch
probability points (MMPPs), which are used to facilitate access to transplantation for
difficult-to-match candidates. One issue is that MMPPs are calculated using a
formula that disregards HLA haplotype linkage disequilibrium <span class="citation"><a href="#ref-Wujciak1997">[132]</a></span>.
A second issue is that at most 100 MMPPs are awarded in ETKAS, which may be
insufficient to provide immunized patients with equality of opportunity
<span class="citation"><a href="#ref-susal2015">[133]</a>, <a href="#ref-ziemannUnacceptableHumanLeucocyte2017">[134]</a>, <a href="#ref-zecherImpactSensitizationWaiting2022a">[135]</a></span>.</p>
</div>
<div id="sec:introam" class="section level3 hasAnchor" number="6.2.2">
<h3><span class="header-section-number">6.2.2</span> Immunized candidates &amp; the Acceptable Mismatch (AM) program<a href="CHprefacekidney.html#sec:introam" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Many kidney transplant candidates have developed
antibodies against donor HLA antigens before they are listed for a kidney transplant,
for instance because of a prior blood transfusion, a pregnancy,
or a previous transplantation. If a donor carries the HLA antigens against which the candidate
has developed such donor-specific antibodies (DSAs), transplantation can be
contraindicated because it is likely to result in antibody-mediated rejection
of the kidney.</p>
<p>In Eurotransplant, transplant centers have historically been required to conduct
a complement-dependent cytotoxicity (CDC) crossmatch before transplantation,
in which the serum of the patient is mixed with lymphocytes isolated from the donor. If such a crossmatch
leads to the cell death of the lymphocytes, transplantation is strongly contraindicated
<span class="citation"><a href="#ref-patelSignificancePositiveCrossmatch1969">[136]</a></span>, and even prohibited in Germany.
In the past, transplantation
centers were also required to regularly test the sera of their patients against
a representative panel of donors to determine their candidates’ panel-reactive antibody (PRA) levels.
Such tests are known as the CDC-PRA tests and the obtained PRA levels quantify
the percentage of the donor pool against which the candidate has a positive
crossmatch. CDC testing could also be used to derive
against which antigens a candidate had developed DSAs, albeit at limited resolution.
Since the 1980s, centers have been able to report such antigens to Eurotransplant
as <em>unacceptable antigens</em>,
which ensures that there candidates would not be offered kidneys that carry those
antigens.</p>
<p>Having a pre-existing immunization can thus prevent a candidate from receiving a
kidney transplant, in particular for candidates with high PRA levels.
This can lead to an accumulation of immunized patients on the waiting list, which
was indeed observed in the late 1980s. In 1988, Frans Claas and Jon van Rood proposed to
strategically select donors for the <em>“hyper-immunized”</em> candidates based on <em>“acceptable antigens”</em>
<span class="citation"><a href="#ref-Claas1988">[137]</a></span>, which formed the basis of the Acceptable Mismatch (AM) program that
was initiated in 1989. These acceptable antigens were defined as antigens against which
an immunized patient had not developed DSAs, and could be identified by crossmatching the candidate’s
serum against panels of HLA-typed blood donors that carried exactly one antigen
mismatch with the patient <span class="citation"><a href="#ref-Claas1988">[137]</a>, <a href="#ref-Heidt2015">[138]</a></span>. In the
AM program, highly immunized candidates (PRA &gt;85%) are given priority
to donors who carried HLA antigens that were either matching with or acceptable to the
candidate. Since its initiation, the AM program has continually been updated by
the Eurotransplant Reference Laboratory (ETRL). For example,
acceptable antigens were initially only defined for HLA-A and HLA-B, while currently
five HLA loci are used for AM allocation <span class="citation"><a href="#ref-ETHist2025">[139]</a></span>.</p>
<p>CDC-PRA assays, in which a candidate’s sera is tested against a panel of donor
lymphocytes, has thus had an important role in determining a candidate’s degree
of immunization. In recent years this technology has largely been replaced by solid-phase assays,
in which the patient’s serum is directly tested against isolated HLA antigens <span class="citation"><a href="#ref-Mamode2022">[140]</a></span>.
Centers regularly screen the sera of their candidates with these solid-phase assays and
report the donor-specific antibodies that are identified using solid-phase assays as unacceptable to
Eurotransplant. Notable is that these solid-phase assays are more sensitive
than CDC-PRA assays, which means that DSAs can be identified that lack
CDC-reactivity. Transplantation in the presence of such DSAs is also associated
with inferior outcomes <span class="citation"><a href="#ref-Amico2009">[141]</a></span>, but not an absolute contraindication <span class="citation"><a href="#ref-Mulley2011">[142]</a></span>.
Instead, European guidelines recommend that the decision to transplant in the
presence of such a DSA should be based on an individualized risk assessment.
This risk assessment should critically evaluate the DSA in light of potential
sensitization events and should assess the impact of designating it as unacceptable
on the likelihood of finding an HLA-compatible kidney <span class="citation"><a href="#ref-Mamode2022">[140]</a></span>.</p>
<p>Since 2016, Eurotransplant calculates a <em>virtual</em> PRA (vPRA) for each candidate
based on their reported unacceptable antigens. This vPRA is defined
as the percentage of donors that carry the unacceptable antigens in a database
of 10,000 donors that is maintained by the ETRL. Advantages of the
vPRA compared to the PRA are (i) that measurement variability associated with the
PRA can be avoided, and (ii) that the vPRA is directly based on unacceptable antigens,
which makes it a better measure of the relative restriction in the
donor pool faced by immunized candidates. In 2020, the vPRA completely replaced the PRA in
kidney allocation in Eurotransplant. For example, mismatch probability points have
been awarded since 2020 based on the vPRA instead of the PRA, and candidates
with a PRA below 85% but a vPRA exceeding 85% can enter the AM program under specific conditions
<span class="citation"><a href="#ref-Heidt2015">[138]</a></span>.<a href="#fn10" class="footnote-ref" id="fnref10"><sup>10</sup></a></p>
</div>
<div id="sec:introesp" class="section level3 hasAnchor" number="6.2.3">
<h3><span class="header-section-number">6.2.3</span> The Eurotransplant Senior Program (ESP)<a href="CHprefacekidney.html#sec:introesp" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>In 1999, Eurotransplant initiated the Eurotransplant Senior Program (ESP), which
is used to offer kidneys from donors 65 years or older with priority to candidates
65 years or older. The aim of ESP was (i) to promote the usage of kidneys from
older donors and (ii) to reduce waiting times for candidates 65 years or older <span class="citation"><a href="#ref-smitsEvaluationEurotransplantSenior2002">[143]</a></span>. These aims were achieved by
prioritizing candidates solely based on their accrued dialysis time and by offering kidneys
only to candidates located in the vicinity of the donor <span class="citation"><a href="#ref-Frei2008">[144]</a></span>. HLA typing
of ESP donors was not performed in order to maximally reduce cold ischemia times.
This meant that transplantations within ESP were done
without consideration of HLA match quality. Because the donor’s HLA typing was
unknown at the time of allocation, immunized candidates were not allowed
to participate in ESP.</p>
<p>Currently, all countries require the HLA typing of ESP donors to be available
before allocation, which has enabled immunized candidates to participate in
ESP. A Eurotransplant paired kidney donation study has demonstrated
that outcomes for patients 65 years or older also improve with HLA-DR matching <span class="citation"><a href="#ref-deFijter2023">[145]</a></span>.
Based on these findings, proposals to prioritize HLA-DR matching in ESP have
been made which are scheduled for implementation in 2025.</p>
</div>
</div>
<div id="contemporary-challenges-in-kidney-allocation" class="section level2 hasAnchor" number="6.3">
<h2><span class="header-section-number">6.3</span> Contemporary challenges in kidney allocation<a href="CHprefacekidney.html#contemporary-challenges-in-kidney-allocation" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>Since the introduction of ETKAS and ESP in the 1990s, the landscape of kidney
transplantation has changed substantially. For example, Eurotransplant’s donor and patient
populations have aged due to demographic developments, and the immunological
evaluation of transplant candidates has changed with the introduction of
solid-phase assays. Despite this changing landscape,
the core principles of Eurotransplant’s kidney allocation systems have remained
largely unchanged. This raises the question of whether these systems adequately
address contemporary challenges in kidney transplantation.</p>
<p>One such challenge concerns the immunized candidates who depend on ETKAS for
access to transplantation. Transplant professionals from Eurotransplant’s kidney transplantation
centers have regularly expressed concerns that this patient group is disadvantaged
in ETKAS. Empirical evidence for such a disadvantage comes from Germany where retrospective analyses have
shown that patients with vPRAs exceeding 85% are disadvantaged
<span class="citation"><a href="#ref-ziemannUnacceptableHumanLeucocyte2017">[134]</a>, <a href="#ref-zecherImpactSensitizationWaiting2022a">[135]</a></span>.
In Chapter <a href="CHvpra.html#CHvpra">7</a>, we examine the relation between the vPRA and the
transplant rate using retrospective data from all Eurotransplant member
countries. We indeed find that immunized candidates face reduced access to
transplantation in ETKAS. European guidelines already recommend that this disparity should be addressed
by directly awarding points for the vPRA using a sliding scale <span class="citation"><a href="#ref-Mamode2022">[140]</a></span>.
In Chapter <a href="CHetkidneysimulator.html#CHetkidneysimulator">8</a>, we design such a sliding scale for ETKAS.</p>
<p>A second challenge comes from the changing patient and donor demographics.
Since the Eurotransplant Senior Program (ESP) was introduced in 1999, the
percentage of patients aged 65 years or older at listing has increased from 6%
in 1999 to 22% in 2024, and the percentage of donors aged 65 years or older has increased
from 11% to 24%. With this changing demographic, concerns have been voiced over the fairness of
ESP. For example, in Germany, the median dialysis time at transplantation
currently differs by more than four years between candidates aged over 65 and
those under 65 <span class="citation"><a href="#ref-Kolbrink2024">[146]</a></span>. This means that a German candidate who starts
dialysis at age 60 is unlikely to receive a kidney transplant until their 65th
birthday, and is expected to be transplanted shortly thereafter.</p>
<p>Eurotransplant also has not implemented any form of candidate-donor age matching
within ETKAS, with the exception of pediatric candidates, who have priority to
kidneys procured from pediatric donors. Organ allocation organizations in France,
the U.K. and the U.S. have all implemented mechanisms which direct kidneys from
young donors to young patients <span class="citation"><a href="#ref-Audry2022">[147]</a>, <a href="#ref-watson2020overview">[148]</a>, <a href="#ref-israniNewNationalAllocation2014">[149]</a></span>.
Calls have been made in the recent literature to also introduce
such continuous candidate-donor age matching in Eurotransplant <span class="citation"><a href="#ref-vonsamson-himmelstjernaContinuousDonorrecipientAge2024">[150]</a></span>.
In Chapter <a href="CHetkidneysimulator.html#CHetkidneysimulator">8</a>, we evaluate a form of continuous-donor
age matching for ETKAS.</p>
<p>A third challenge is that ETKAS has continued to place equal emphasis on HLA-A,
HLA-B, and HLA-DR matching, while virtually all other organ exchange organizations
emphasize matching at the HLA-DR locus, or matching at both the HLA-B and HLA-DR loci
<span class="citation"><a href="#ref-Wu2017">[151]</a></span>. In Chapter <a href="CHetkidneysimulator.html#CHetkidneysimulator">8</a>, we examine how waiting list
outcomes are affected if more priority is given to matching at the HLA-B
and HLA-DR loci.</p>
<p>This thesis explores several directions in which kidney allocation in
Eurotransplant could be improved. Instrumental to studying the impact of
these policy changes is
the ETKidney simulator, a discrete-event simulator that mimics ETKAS and
ESP allocation based on data from the Eurotransplant database. We describe and validate this simulator
in Chapter <a href="CHetkidneysimulator.html#CHetkidneysimulator">8</a>.</p>

</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body" entry-spacing="0">
<div id="ref-vanRoodET1967" class="csl-entry">
<div class="csl-left-margin">[1] </div><div class="csl-right-inline">J. J. van Rood, <span>“A proposal for international cooperation in organ transplantation: <span>Eurotransplant</span>,”</span> in <em>Histocompatibility testing 1967: Report of a conference and workshop, torino and saint-vincent, italy, 14–24 june 1967</em>, R. Curtoni, P. Mattiuz, and R. Tosi, Eds., Copenhagen, Denmark, 1967, pp. 451–452.</div>
</div>
<div id="ref-HaaseKromwijk1999" class="csl-entry">
<div class="csl-left-margin">[7] </div><div class="csl-right-inline">B. J. J. M. Haase-Kromwijk, J. de Meester, and G. G. Persijn, <span>“<span>Eurotransplant Foundation</span>: The original framework of organ exchange,”</span> <em>Best Practice &amp; Research Clinical Anaesthesiology</em>, vol. 13, no. 2, pp. 169–178, 1999, doi: <a href="https://doi.org/10.1053/bean.1999.0018">10.1053/bean.1999.0018</a>.</div>
</div>
<div id="ref-Persijn2006" class="csl-entry">
<div class="csl-left-margin">[8] </div><div class="csl-right-inline">G. G. Persijn, <span>“Allocation of organs, particularly kidneys, within <span>Eurotransplant</span>,”</span> <em>Human Immunology</em>, vol. 67, no. 6, pp. 419–423, 2006, doi: <a href="https://doi.org/10.1016/j.humimm.2006.03.008">10.1016/j.humimm.2006.03.008</a>.</div>
</div>
<div id="ref-demeesterNewEurotransplantKidney1998" class="csl-entry">
<div class="csl-left-margin">[15] </div><div class="csl-right-inline">J. de Meester, G. G. Persijn, T. Wujciak, G. Opelz, and Y. Vanrenterghem, <span>“The new <span>Eurotransplant</span> kidney allocation system: Report one year after implementation.”</span> <em>Transplantation</em>, vol. 66, no. 9, pp. 1154–1159, 1998, doi: <a href="https://doi.org/10.1097/00007890-199811150-00007">10.1097/00007890-199811150-00007</a>.</div>
</div>
<div id="ref-glander2010" class="csl-entry">
<div class="csl-left-margin">[17] </div><div class="csl-right-inline">P. Glander <em>et al.</em>, <span>“The ‘blood group <span>O</span> problem’ in kidney transplantation — time to change?”</span> <em>Nephrology Dialysis Transplantation</em>, vol. 25, no. 6, pp. 1998–2004, 2010, doi: <a href="https://doi.org/10.1093/ndt/gfp779">10.1093/ndt/gfp779</a>.</div>
</div>
<div id="ref-Vanholder2021" class="csl-entry">
<div class="csl-left-margin">[104] </div><div class="csl-right-inline">R. Vanholder <em>et al.</em>, <span>“Fighting the unbearable lightness of neglecting kidney health: The decade of the kidney,”</span> <em>Clinical Kidney Journal</em>, vol. 14, no. 7, pp. 1719–1730, 2021, doi: <a href="https://doi.org/10.1093/ckj/sfab070">10.1093/ckj/sfab070</a>.</div>
</div>
<div id="ref-Tonelli2011" class="csl-entry">
<div class="csl-left-margin">[105] </div><div class="csl-right-inline">M. Tonelli <em>et al.</em>, <span>“Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes,”</span> <em>American Journal of Transplantation</em>, vol. 11, no. 10, pp. 2093–2109, 2011, doi: <a href="https://doi.org/10.1111/j.1600-6143.2011.03686.x">10.1111/j.1600-6143.2011.03686.x</a>.</div>
</div>
<div id="ref-eurotransplantAR2005" class="csl-entry">
<div class="csl-left-margin">[106] </div><div class="csl-right-inline">Eurotransplant International Foundation, <span>“<span>Annual Report 2005</span>.”</span> 2005. Available: <a href="https://www.eurotransplant.org/wp-content/uploads/2019/12/ar_2005.pdf">https://www.eurotransplant.org/wp-content/uploads/2019/12/ar_2005.pdf</a></div>
</div>
<div id="ref-vanDorp2001" class="csl-entry">
<div class="csl-left-margin">[107] </div><div class="csl-right-inline">M. H. van Dorp, <span>“<span>HLA</span> &amp; <span class="nocase">transplantatie</span>: De ontwikkeling van een matchingspraktijk,”</span> PhD thesis, University of Maastricht, 2001. doi: <a href="https://doi.org/10.26481/dis.20011116md">10.26481/dis.20011116md</a>.</div>
</div>
<div id="ref-bakJensenShareNotShare2008" class="csl-entry">
<div class="csl-left-margin">[108] </div><div class="csl-right-inline">S. Bak-Jensen, <span>“To share or not to <span class="nocase">share? institutional</span> exchange of cadaver kidneys in <span>Denmark</span>,”</span> <em>Medical History</em>, vol. 52, no. 1, pp. 23–46, 2008, doi: <a href="https://doi.org/10.1017/S0025727300002040">10.1017/S0025727300002040</a>.</div>
</div>
<div id="ref-daussetHLAStory1995" class="csl-entry">
<div class="csl-left-margin">[109] </div><div class="csl-right-inline">J. Dausset and F. T. Rapaport, <span>“<span>The</span> <span>HLA</span> <span>Story</span>,”</span> in <em>Immunology</em>, R. B. Gallagher, J. Gilder, G. J. V. Nossal, and G. Salvatore, Eds., London: Academic Press, 1995, ch. 10, pp. 111–120. doi: <a href="https://doi.org/10.1016/B978-012274020-6/50011-8">10.1016/B978-012274020-6/50011-8</a>.</div>
</div>
<div id="ref-vanRood2004" class="csl-entry">
<div class="csl-left-margin">[110] </div><div class="csl-right-inline">J. J. van Rood, <span>“Weighing optimal graft survival through <span>HLA</span> matching against the equitable distribution of kidney allografts,”</span> <em>New England Journal of Medicine</em>, vol. 350, no. 6, pp. 535–536, 2004, doi: <a href="https://doi.org/10.1056/nejmp030011">10.1056/nejmp030011</a>.</div>
</div>
<div id="ref-Persijn1978" class="csl-entry">
<div class="csl-left-margin">[111] </div><div class="csl-right-inline">G. G. Persijn, B. W. Gabb, A. van Leeuwen, A. Nagtegaal, J. Hoogeboom, and J. J. van Rood, <span>“Matching for <span>HLA</span> of <span>A,</span> <span>B,</span> and <span>DR</span> loci in renal transplantation by <span>Eurotransplant</span>,”</span> <em>The Lancet</em>, vol. 311, no. 8077, pp. 1278–1281, 1978, doi: <a href="https://doi.org/10.1016/s0140-6736(78)91266-7">10.1016/s0140-6736(78)91266-7</a>.</div>
</div>
<div id="ref-Persijn1981" class="csl-entry">
<div class="csl-left-margin">[112] </div><div class="csl-right-inline">G. G. Persijn <em>et al.</em>, <span>“<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2385780">Improved kidney graft survival in <span>Eurotransplant</span> by <span>HLA-DR</span> matching and prospectively given blood transfusions</a>,”</span> <em>The Ulster Medical Journal</em>, vol. 50, no. Suppl 1, pp. 54–61, 1981.</div>
</div>
<div id="ref-terasaki1990history" class="csl-entry">
<div class="csl-left-margin">[113] </div><div class="csl-right-inline">P. I. Terasaki <em>et al.</em>, <span>“History of <span>HLA</span>: <span>A</span> personalized view,”</span> in <em>History of <span>HLA</span>: <span>Ten</span> <span>Recollections</span></em>, UCLA Tissue Typing Laboratory, 1990, ch. 10, pp. 232–233. Available: <a href="http://www.piterasaki.org/HistoryOfHLA.pdf">http://www.piterasaki.org/HistoryOfHLA.pdf</a></div>
</div>
<div id="ref-Kjellstrand1988" class="csl-entry">
<div class="csl-left-margin">[114] </div><div class="csl-right-inline">C. M. Kjellstrand, <span>“Age, sex, and race inequality in renal transplantation,”</span> <em>Archives of Internal Medicine</em>, vol. 148, no. 6, p. 1305, 1988, doi: <a href="https://doi.org/10.1001/archinte.1988.00380060069016">10.1001/archinte.1988.00380060069016</a>.</div>
</div>
<div id="ref-starzlMultifactorialSystemEquitable1987" class="csl-entry">
<div class="csl-left-margin">[115] </div><div class="csl-right-inline">T. E. Starzl <em>et al.</em>, <span>“<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949292">A multifactorial system for equitable selection of cadaver kidney recipients</a>,”</span> <em>JAMA</em>, vol. 257, no. 22, pp. 3073–3075, 1987.</div>
</div>
<div id="ref-greensteinEvidenceThatZero1990" class="csl-entry">
<div class="csl-left-margin">[116] </div><div class="csl-right-inline">S. M. Greenstein <em>et al.</em>, <span>“Evidence that zero antigen-matched cyclosporine-treated renal transplant recipients have graft survival equal to that of matched recipients. Reevaluation of points,”</span> <em>Transplantation</em>, vol. 49, no. 2, pp. 332–336, 1990, doi: <a href="https://doi.org/10.1097/00007890-199002000-00021">10.1097/00007890-199002000-00021</a>.</div>
</div>
<div id="ref-harfmannRenalTransplantationUsing1989" class="csl-entry">
<div class="csl-left-margin">[117] </div><div class="csl-right-inline">P. Harfmann, R. Dittmer, R. Busch, R. Arndt, H. Krämer-Hansen, and H. Huland, <span>“Renal transplantation using cyclosporine with and without regard to <span>HLA</span> matching: A randomized prospective unicenter study,”</span> <em>The Journal of Urology</em>, vol. 142, no. 3, pp. 691–693, 1989, doi: <a href="https://doi.org/10.1016/S0022-5347(17)38854-7">10.1016/S0022-5347(17)38854-7</a>.</div>
</div>
<div id="ref-opelzCORRELATIONHLAMATCHING1985" class="csl-entry">
<div class="csl-left-margin">[118] </div><div class="csl-right-inline">G. Opelz, <span>“Correlation of <span>HLA</span> matching with kidney graft survival in patients with or without cyclosporine treatment: For the <span>Collaborative Transplant Study</span>,”</span> <em>Transplantation</em>, vol. 40, no. 3, p. 240, 1985, doi: <a href="https://doi.org/10.1097/00007890-198509000-00003">10.1097/00007890-198509000-00003</a>.</div>
</div>
<div id="ref-Opelz2007" class="csl-entry">
<div class="csl-left-margin">[119] </div><div class="csl-right-inline">G. Opelz and B. Döhler, <span>“Effect of human leukocyte antigen compatibility on kidney graft survival: Comparative analysis of two decades,”</span> <em>Transplantation</em>, vol. 84, no. 2, pp. 137–143, 2007, doi: <a href="https://doi.org/10.1097/01.tp.0000269725.74189.b9">10.1097/01.tp.0000269725.74189.b9</a>.</div>
</div>
<div id="ref-morrisAnalysisFactorsThat1999" class="csl-entry">
<div class="csl-left-margin">[120] </div><div class="csl-right-inline">P. J. Morris, R. J. Johnson, S. V. Fuggle, M. A. Belger, and J. D. Briggs, <span>“Analysis of factors that affect outcome of primary cadaveric renal transplantation in the <span>UK.</span> <span>HLA</span> task force of the kidney advisory group of the <span>United Kingdom</span> transplant support service authority <span>(UKTSSA)</span>,”</span> <em>The Lancet</em>, vol. 354, no. 9185, pp. 1147–1152, 1999, doi: <a href="https://doi.org/10.1016/s0140-6736(99)01104-6">10.1016/s0140-6736(99)01104-6</a>.</div>
</div>
<div id="ref-CICCIARELLI1987" class="csl-entry">
<div class="csl-left-margin">[121] </div><div class="csl-right-inline">J. Cicciarelli, P. I. Terasaki, and M. R. Mickey, <span>“The effect of zero <span>HLA</span> class <span>I</span> and <span>II</span> mismatching in cyclosporine-treated kidney transplant patients,”</span> <em>Transplantation</em>, vol. 43, no. 5, pp. 636–640, 1987, doi: <a href="https://doi.org/10.1097/00007890-198705000-00006">10.1097/00007890-198705000-00006</a>.</div>
</div>
<div id="ref-Ting1985" class="csl-entry">
<div class="csl-left-margin">[122] </div><div class="csl-right-inline">A. Ting and P. J. Morris, <span>“The role of <span>HLA</span> matching in renal transplantation,”</span> <em>Tissue Antigens</em>, vol. 25, no. 5, pp. 225–234, 1985, doi: <a href="https://doi.org/10.1111/j.1399-0039.1985.tb00445.x">10.1111/j.1399-0039.1985.tb00445.x</a>.</div>
</div>
<div id="ref-joyseyTissueTypingPolicy1989" class="csl-entry">
<div class="csl-left-margin">[123] </div><div class="csl-right-inline">V. C. Joysey, <span>“Tissue typing policy,”</span> in <em>Transplantation</em>, G. R. D. Catto, Ed., Dordrecht, 1989, pp. 59–93. doi: <a href="https://doi.org/10.1007/978-94-009-0855-0_3">10.1007/978-94-009-0855-0_3</a>.</div>
</div>
<div id="ref-thorogood1990" class="csl-entry">
<div class="csl-left-margin">[124] </div><div class="csl-right-inline">J. Thorogood <em>et al.</em>, <span>“The effect of <span>HLA</span> matching on kidney graft survival in separate posttransplantation intervals,”</span> <em>Transplantation</em>, vol. 50, no. 1, p. 146, 1990, doi: <a href="https://doi.org/10.1097/00007890-199007000-00027">10.1097/00007890-199007000-00027</a>.</div>
</div>
<div id="ref-DeMeester1998_booksection" class="csl-entry">
<div class="csl-left-margin">[125] </div><div class="csl-right-inline">J. de Meester and G. G. Persijn, <span>“Allocation of cadaver organs to transplant recipients in <span>Eurotransplant:</span> Principles and policies, anno 1998,”</span> in <em>Organ <span>Allocation</span>: <span>Proceedings</span> of the 30th <span>Conference</span> on <span>Transplantation</span> and <span>Clinical</span> <span>Immunology</span>, 2–4 <span>June</span>, 1998</em>, J. L. Touraine, J. Traeger, H. Bétuel, J. M. Dubernard, J. P. Revillard, and C. Dupuy, Eds., Dordrecht, 1998, pp. 61–66. doi: <a href="https://doi.org/10.1007/978-94-011-4984-6_8">10.1007/978-94-011-4984-6_8</a>.</div>
</div>
<div id="ref-wujciakProposalImprovedCadaver1993a" class="csl-entry">
<div class="csl-left-margin">[126] </div><div class="csl-right-inline">T. Wujciak and G. Opelz, <span>“A proposal for improved cadaver kidney allocation,”</span> <em>Transplantation</em>, vol. 56, no. 6, pp. 1513–1517, 1993, doi: <a href="https://doi.org/10.1097/00007890-199312000-00044">10.1097/00007890-199312000-00044</a>.</div>
</div>
<div id="ref-Opelz1998" class="csl-entry">
<div class="csl-left-margin">[127] </div><div class="csl-right-inline">G. Opelz and T. Wujciak, <span>“What to expect from a good kidney allocation system,”</span> in <em>Organ allocation: <span>Proceedings</span> of the 30th conference on transplantation and clinical immunology, 2–4 june, 1998</em>, J. L. Touraine, J. Traeger, H. Bétuel, J. M. Dubernard, J. P. Revillard, and C. Dupuy, Eds., Dordrecht, 1998, pp. 57–60. doi: <a href="https://doi.org/10.1007/978-94-011-4984-6_7">10.1007/978-94-011-4984-6_7</a>.</div>
</div>
<div id="ref-DeMeester2000" class="csl-entry">
<div class="csl-left-margin">[128] </div><div class="csl-right-inline">J. de Meester, G. G. Persijn, F. H. J. Claas, and U. Frei, <span>“In the queue for a cadaver donor kidney transplant: New rules and concepts in the <span>Eurotransplant</span>,”</span> <em>Nephrology Dialysis Transplantation</em>, vol. 15, no. 3, pp. 333–338, 2000, doi: <a href="https://doi.org/10.1093/ndt/15.3.333">10.1093/ndt/15.3.333</a>.</div>
</div>
<div id="ref-vereerstraetenExperienceWujciakOpelzAllocation1998" class="csl-entry">
<div class="csl-left-margin">[129] </div><div class="csl-right-inline">P. Vereerstraeten, D. Abramowicz, L. De Pauw, and P. Kinnaert, <span>“Experience with the <span>Wujciak-Opelz</span> allocation system in a single center: An increase in <span>HLA-DR</span> mismatching and in early occurring acute rejection episodes,”</span> <em>Transplant International</em>, vol. 11, no. 5, pp. 378–381, 1998, doi: <a href="https://doi.org/10.1007/s001470050161">10.1007/s001470050161</a>.</div>
</div>
<div id="ref-doxiadisSimplerEquitableAllocation2007" class="csl-entry">
<div class="csl-left-margin">[130] </div><div class="csl-right-inline">I. I. N. Doxiadis <em>et al.</em>, <span>“Simpler and equitable allocation of kidneys from postmortem donors primarily based on full <span>HLA-DR</span> compatibility,”</span> <em>Transplantation</em>, vol. 83, no. 9, p. 1207, 2007, doi: <a href="https://doi.org/10.1097/01.tp.0000261108.27421.bc">10.1097/01.tp.0000261108.27421.bc</a>.</div>
</div>
<div id="ref-heemskerkRegionalKidneyAllocation2009" class="csl-entry">
<div class="csl-left-margin">[131] </div><div class="csl-right-inline">M. B. A. Heemskerk <em>et al.</em>, <span>“Regional kidney allocation based only on full <span>HLA-DR</span> compatibility is not feasible,”</span> <em>Transplantation</em>, vol. 88, no. 4, p. 600, 2009, doi: <a href="https://doi.org/10.1097/TP.0b013e3181b16174">10.1097/TP.0b013e3181b16174</a>.</div>
</div>
<div id="ref-Wujciak1997" class="csl-entry">
<div class="csl-left-margin">[132] </div><div class="csl-right-inline">T. Wujciak and G. Opelz, <span>“Matchability as an important factor for kidney allocation according to the <span>HLA</span> match,”</span> <em>Transplantation Proceedings</em>, vol. 29, no. 1–2, pp. 1403–1405, 1997, doi: <a href="https://doi.org/10.1016/s0041-1345(96)00610-0">10.1016/s0041-1345(96)00610-0</a>.</div>
</div>
<div id="ref-susal2015" class="csl-entry">
<div class="csl-left-margin">[133] </div><div class="csl-right-inline">C. Süsal and C. Morath, <span>“Virtual <span>PRA</span> replaces traditional pra: Small change but significantly more justice for sensitized patients,”</span> <em>Transplant International</em>, vol. 28, no. 6, pp. 708–709, 2015, doi: <a href="https://doi.org/10.1111/tri.12572">10.1111/tri.12572</a>.</div>
</div>
<div id="ref-ziemannUnacceptableHumanLeucocyte2017" class="csl-entry">
<div class="csl-left-margin">[134] </div><div class="csl-right-inline">M. Ziemann <em>et al.</em>, <span>“Unacceptable human leukocyte antigens for organ offers in the era of organ shortage: Influence on waiting time before kidney transplantation,”</span> <em>Nephrology Dialysis Transplantation</em>, vol. 32, no. 5, pp. 880–889, 2017, doi: <a href="https://doi.org/10.1093/ndt/gfw462">10.1093/ndt/gfw462</a>.</div>
</div>
<div id="ref-zecherImpactSensitizationWaiting2022a" class="csl-entry">
<div class="csl-left-margin">[135] </div><div class="csl-right-inline">D. Zecher <em>et al.</em>, <span>“Impact of sensitization on waiting time prior to kidney transplantation in <span>Germany</span>,”</span> <em>Transplantation</em>, vol. 106, no. 12, p. 2448, 2022, doi: <a href="https://doi.org/10.1097/TP.0000000000004238">10.1097/TP.0000000000004238</a>.</div>
</div>
<div id="ref-patelSignificancePositiveCrossmatch1969" class="csl-entry">
<div class="csl-left-margin">[136] </div><div class="csl-right-inline">R. Patel and P. I. Terasaki, <span>“Significance of the positive crossmatch test in kidney transplantation,”</span> <em>The New England Journal of Medicine</em>, vol. 280, no. 14, pp. 735–739, 1969, doi: <a href="https://doi.org/10.1056/NEJM196904032801401">10.1056/NEJM196904032801401</a>.</div>
</div>
<div id="ref-Claas1988" class="csl-entry">
<div class="csl-left-margin">[137] </div><div class="csl-right-inline">F. H. J. Claas and J. J. van Rood, <span>“The hyperimmunized patient: From sensitization toward transplantation,”</span> <em>Transplant International</em>, vol. 1, no. 2, pp. 53–57, 1988, doi: <a href="https://doi.org/10.1007/bf00353819">10.1007/bf00353819</a>.</div>
</div>
<div id="ref-Heidt2015" class="csl-entry">
<div class="csl-left-margin">[138] </div><div class="csl-right-inline">S. Heidt, M. D. Witvliet, G. W. Haasnoot, and F. H. J. Claas, <span>“The 25th anniversary of the <span>Eurotransplant</span> <span class="nocase">Acceptable Mismatch program</span> for highly sensitized patients,”</span> <em>Transplant Immunology</em>, vol. 33, no. 2, pp. 51–57, 2015, doi: <a href="https://doi.org/10.1016/j.trim.2015.08.006">10.1016/j.trim.2015.08.006</a>.</div>
</div>
<div id="ref-ETHist2025" class="csl-entry">
<div class="csl-left-margin">[139] </div><div class="csl-right-inline">Eurotransplant, <span>“<span>Eurotransplant Manual</span>. <span>Chapter 10: Histocompatibility Testing</span>.”</span> Available: <a href="https://www.eurotransplant.org/allocation/eurotransplant-manual/">https://www.eurotransplant.org/allocation/eurotransplant-manual/</a></div>
</div>
<div id="ref-Mamode2022" class="csl-entry">
<div class="csl-left-margin">[140] </div><div class="csl-right-inline">N. Mamode <em>et al.</em>, <span>“<span>European</span> guideline for the management of kidney transplant patients with <span>HLA</span> antibodies: By the <span>European</span> society for organ transplantation working group,”</span> <em>Transplant International</em>, vol. 35, 2022, doi: <a href="https://doi.org/10.3389/ti.2022.10511">10.3389/ti.2022.10511</a>.</div>
</div>
<div id="ref-Amico2009" class="csl-entry">
<div class="csl-left-margin">[141] </div><div class="csl-right-inline">P. Amico, G. Hönger, M. Mayr, J. Steiger, H. Hopfer, and S. Schaub, <span>“Clinical relevance of pretransplant donor-specific <span>HLA</span> antibodies detected by single-antigen flow-beads,”</span> <em>Transplantation</em>, vol. 87, no. 11, pp. 1681–1688, 2009, doi: <a href="https://doi.org/10.1097/tp.0b013e3181a5e034">10.1097/tp.0b013e3181a5e034</a>.</div>
</div>
<div id="ref-Mulley2011" class="csl-entry">
<div class="csl-left-margin">[142] </div><div class="csl-right-inline">W. R. Mulley and J. Kanelles, <span>“Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologist,”</span> <em>Nephrology</em>, vol. 16, no. 2, pp. 125–133, 2011, doi: <a href="https://doi.org/10.1111/j.1440-1797.2010.01414.x">10.1111/j.1440-1797.2010.01414.x</a>.</div>
</div>
<div id="ref-smitsEvaluationEurotransplantSenior2002" class="csl-entry">
<div class="csl-left-margin">[143] </div><div class="csl-right-inline">J. M. A. Smits, G. G. Persijn, J. C. van Houwelingen, F. H. J. Claas, and U. Frei, <span>“Evaluation of the <span>Eurotransplant</span> <span>Senior Program</span>. The results of the first year,”</span> <em>American Journal of Transplantation</em>, vol. 2, no. 7, pp. 664–670, 2002, doi: <a href="https://doi.org/10.1034/j.1600-6143.2002.20713.x">10.1034/j.1600-6143.2002.20713.x</a>.</div>
</div>
<div id="ref-Frei2008" class="csl-entry">
<div class="csl-left-margin">[144] </div><div class="csl-right-inline">U. Frei <em>et al.</em>, <span>“Prospective age-matching in elderly kidney transplant recipients - a 5-year analysis of the <span>Eurotransplant</span> <span>Senior Program</span>,”</span> <em>American Journal of Transplantation</em>, vol. 8, no. 1, pp. 50–57, 2008, doi: <a href="https://doi.org/10.1111/j.1600-6143.2007.02014.x">10.1111/j.1600-6143.2007.02014.x</a>.</div>
</div>
<div id="ref-deFijter2023" class="csl-entry">
<div class="csl-left-margin">[145] </div><div class="csl-right-inline">J. de Fijter <em>et al.</em>, <span>“A paired-kidney allocation study found superior survival with <span>HLA-DR</span> compatible kidney transplants in the <span>Eurotransplant</span> <span>Senior Program</span>,”</span> <em>Kidney International</em>, vol. 104, no. 3, pp. 552–561, 2023, doi: <a href="https://doi.org/10.1016/j.kint.2023.05.025">10.1016/j.kint.2023.05.025</a>.</div>
</div>
<div id="ref-Kolbrink2024" class="csl-entry">
<div class="csl-left-margin">[146] </div><div class="csl-right-inline">B. Kolbrink <em>et al.</em>, <span>“Allocation rules and age-dependent waiting times for kidney transplantation,”</span> <em>Deutsches Ärzteblatt international</em>, 2024, doi: <a href="https://doi.org/10.3238/arztebl.m2024.0137">10.3238/arztebl.m2024.0137</a>.</div>
</div>
<div id="ref-Audry2022" class="csl-entry">
<div class="csl-left-margin">[147] </div><div class="csl-right-inline">B. Audry <em>et al.</em>, <span>“The new <span>French</span> kidney allocation system for donations after brain death: Rationale, implementation, and evaluation,”</span> <em>American Journal of Transplantation</em>, vol. 22, no. 12, pp. 2855–2868, 2022, doi: <a href="https://doi.org/10.1111/ajt.17180">10.1111/ajt.17180</a>.</div>
</div>
<div id="ref-watson2020overview" class="csl-entry">
<div class="csl-left-margin">[148] </div><div class="csl-right-inline">C. J. E. Watson, R. J. Johnson, and L. Mumford, <span>“Overview of the evolution of the <span>UK</span> kidney allocation schemes,”</span> <em>Current Transplantation Reports</em>, vol. 7, no. 2, pp. 140–144, 2020, doi: <a href="https://doi.org/10.1007/s40472-020-00270-6">10.1007/s40472-020-00270-6</a>.</div>
</div>
<div id="ref-israniNewNationalAllocation2014" class="csl-entry">
<div class="csl-left-margin">[149] </div><div class="csl-right-inline">A. K. Israni <em>et al.</em>, <span>“New national allocation policy for deceased donor kidneys in the <span>United States</span> and possible effect on patient outcomes,”</span> <em>Journal of the American Society of Nephrology</em>, vol. 25, no. 8, pp. 1842–1848, 2014, doi: <a href="https://doi.org/10.1681/ASN.2013070784">10.1681/ASN.2013070784</a>.</div>
</div>
<div id="ref-vonsamson-himmelstjernaContinuousDonorrecipientAge2024" class="csl-entry">
<div class="csl-left-margin">[150] </div><div class="csl-right-inline">F. A. von Samson-Himmelstjerna, B. Kolbrink, K. Budde, R. Schmitt, and K. Schulte, <span>“Continuous donor-recipient age matching: A chance for kidney allocation in the <span>Eurotransplant</span> region,”</span> <em>American Journal of Transplantation</em>, 2024, doi: <a href="https://doi.org/10.1016/j.ajt.2024.11.022">10.1016/j.ajt.2024.11.022</a>.</div>
</div>
<div id="ref-Wu2017" class="csl-entry">
<div class="csl-left-margin">[151] </div><div class="csl-right-inline">D. A. Wu, C. J. Watson, J. A. Bradley, R. J. Johnson, J. L. Forsythe, and G. C. Oniscu, <span>“Global trends and challenges in deceased donor kidney allocation,”</span> <em>Kidney International</em>, vol. 91, no. 6, pp. 1287–1299, 2017, doi: <a href="https://doi.org/10.1016/j.kint.2016.09.054">10.1016/j.kint.2016.09.054</a>.</div>
</div>
</div>
<div class="footnotes">
<hr />
<ol start="10">
<li id="fn10"><p>For the AM program,
unacceptable antigens either require CDC
reactivity, or documentation that links the DSA to a sensitizing event.<a href="CHprefacekidney.html#fnref10" class="footnote-back">↩︎</a></p></li>
</ol>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="CHelassimulator.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="CHvpra.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": ["thesis.pdf"],
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.9/latest.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
